Honeybee venom showed high anticancer selectivity, with a significantly higher potency in TNBC (e.g., SUM159 and SUM149) and in the HER2-enriched breast cancer cell lines (e.g., MDA-MB-453 and SKBR3), followed by luminal breast cancer cells (including MCF7 and T-47D), with the lowest impact on normal cells (primary dermal fibroblast cells HDFa, and mammary nontransformed MCF 10A and MCF-12A cells) (Fig. 1b, left; Table 1; GLM, Wald Chi-Square = 342, p < 0.001, n = 33, df = 1). Here, ERBB2 is linked to breast cancer.